T Sioris

Summary

Country: Finland

Publications

  1. ncbi Effect of surgical volume and hospital type on outcome in non-small cell lung cancer surgery: a Finnish population-based study
    Thanos Sioris
    Tampere University Hospital, Heart Center, P O Box 2000, FIN 33521 Tampere, Finland
    Lung Cancer 59:119-25. 2008
  2. ncbi Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis
    T Sioris
    Heart Center, Tampere University Hospital, P O Box 2000, FIN 33521 Tampere, Finland
    Eur J Surg Oncol 35:546-51. 2009
  3. ncbi Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure
    T Sioris
    Department of Surgery, Tampere University Hospital, Tampere, Finland
    Int J Cancer 86:590-4. 2000
  4. ncbi Immunostaining for detecting lymph node metastases in non-small cell lung cancer
    T Sioris
    Department of Cardiothoracic Surgery, Tampere University Hospital, Finland
    Scand Cardiovasc J 34:536-40. 2000
  5. ncbi Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients
    Lea Pylkkanen
    Department of Industrial Hygiene and Toxicology, Finnish Institute of Occupational Health, Helsinki, Finland
    Int J Oncol 20:285-90. 2002
  6. ncbi Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer
    Thanos Sioris
    Department of Cardiothoracic Surgery, Tampere University Hospital, Tampere, Finland
    Eur J Cardiothorac Surg 23:403-8. 2003
  7. ncbi Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays
    Harriet Wikman
    Departments of Medical Genetics and Pathology, Haartman Institute, University of Helsinki and Helsinki University Central Hospital Laboratory Diagnostics, Helsinki, Finland
    J Pathol 203:584-93. 2004

Collaborators

  • S Anttila
  • K Husgafvel-Pursiainen
  • A Knuuttila
  • Harriet Wikman
  • Antti Karjalainen
  • Lea Pylkkanen
  • Sakari Knuutila
  • Katri Vainio-Siukola
  • Eeva Kuosma
  • Jarmo Salo
  • Kaisa Salmenkivi
  • Balint Nagy
  • Virinder K Sarhadi
  • Eeva Kettunen
  • Paivi Tuominen
  • Henrik Wolff
  • Tuula Stjernvall

Detail Information

Publications7

  1. ncbi Effect of surgical volume and hospital type on outcome in non-small cell lung cancer surgery: a Finnish population-based study
    Thanos Sioris
    Tampere University Hospital, Heart Center, P O Box 2000, FIN 33521 Tampere, Finland
    Lung Cancer 59:119-25. 2008
    ....
  2. ncbi Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis
    T Sioris
    Heart Center, Tampere University Hospital, P O Box 2000, FIN 33521 Tampere, Finland
    Eur J Surg Oncol 35:546-51. 2009
    ..Incomplete lung expansion after fluid evacuation, and/or excessive fluid secretion predicts failure of pleurodesis. A mini-invasive alternative was investigated...
  3. ncbi Survival in operable non-small-cell lung cancer: role of p53 mutations, tobacco smoking and asbestos exposure
    T Sioris
    Department of Surgery, Tampere University Hospital, Tampere, Finland
    Int J Cancer 86:590-4. 2000
    ..In adenocarcinoma, p53 mutation, in addition to stage, emerged as a significant predictor of poor cancer-related survival...
  4. ncbi Immunostaining for detecting lymph node metastases in non-small cell lung cancer
    T Sioris
    Department of Cardiothoracic Surgery, Tampere University Hospital, Finland
    Scand Cardiovasc J 34:536-40. 2000
    ..To detect lymph node metastases by immunohistochemistry, where previously undetected by routine histopathology...
  5. ncbi Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients
    Lea Pylkkanen
    Department of Industrial Hygiene and Toxicology, Finnish Institute of Occupational Health, Helsinki, Finland
    Int J Oncol 20:285-90. 2002
    ..5, 95% CI 0.9-7.4), and in poorly differentiated tumours (grade 3, OR 2.6, 95% CI 0.8-8.1). In conclusion, our present data support significance of FHIT inactivation in development of lung cancer...
  6. ncbi Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer
    Thanos Sioris
    Department of Cardiothoracic Surgery, Tampere University Hospital, Tampere, Finland
    Eur J Cardiothorac Surg 23:403-8. 2003
    ..To compare computed tomography (CT)-based clinical TNM and staging to surgical-pathological staging with systematic lymph node dissection in primary non-small cell lung cancer...
  7. ncbi Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays
    Harriet Wikman
    Departments of Medical Genetics and Pathology, Haartman Institute, University of Helsinki and Helsinki University Central Hospital Laboratory Diagnostics, Helsinki, Finland
    J Pathol 203:584-93. 2004
    ..Some of these genes may provide novel diagnostic markers for lung cancer...